Top Markets
#1 Black Phoenix Black Phoenix +829.97%
#2 pipedog pipedog +41.42%
#3 PondCoin PondCoin +34.34%
#4 Bless Bless +32.22%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.51%
#7 Beam Beam +24.69%
#8 Magma Finance Magma Finance +19.36%
#9 Seeker Seeker +19.26%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Classement en actions #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Prix de l'action
$64.97
Dernière synchronisation: 2024-05-20
Capitalisation boursière
$1.97B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Alpine Immune Sciences, Inc. (ALPN)

Catégorie

Healthcare
Revenus pour Alpine Immune Sciences, Inc. (ALPN)
Revenus en Mar 2024 TTM : $56.52M
Selon les derniers rapports financiers de Alpine Immune Sciences, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $56.52M. En 2022, l'entreprise a réalisé un chiffre d'affaires de $30.06M une augmentation par rapport à le chiffre d'affaires de l'année 2021, qui était de $23.44M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Alpine Immune Sciences, Inc. de 2012 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
2026 (TTM) $56.52M -4.00%
2023 $58.88M 95.84%
2022 $30.06M 28.24%
2021 $23.44M 151.13%
2020 $9.34M 436.49%
2019 $1.74M 146.81%
2018 $705.00K -59.27%
2017 $1.73M -41.32%
2016 $2.95M 499.59%
2015 $492.00K 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 22,235.59%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 10,553.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 27,755.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 3,841.90%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH